Table 1.
Baseline information before second-line antiretroviral treatment
| Variable | Category | Numerical value |
|---|---|---|
| Gender (n. %) | Male | 73(60.8%) |
| Female | 47(39.2%) | |
| Age (years, IQR) | 45.2(39.8–52.3) | |
| Education degree (n, %) | Primary school | 61(50.8%) |
| Junior middle school | 40(33.3%) | |
| Illiteracy | 19(15.8%) | |
| Occupation (n, %) | Farmer | 120(100%) |
| Route of infection (n, %) | Paid blood donation(blood transfusion) | 115(95.8%) |
| Heterosexual | 3(2.5%) | |
| Blood transfusion | 1(0.8%) | |
| Unknown | 1(0.8%) | |
| Duration of first-line treatment (years, IQR) | 5.0(3.7–5.5) | |
| NRTIs drug resistance (n, %) | 68(58.1%) | |
| 3TC drug resistance | 38(32.5%) | |
| TDF drug resistance | 57(48.7%) | |
| NNRTIs drug resistance (n, %) | 84(71.8%) | |
| Lpv/r drug resistance (n, %) | 0(0) | |
| Baseline viral load (lg10) (median, IQR) copies/ml | 4.58 (3.96–5.17) | |
| Baseline CD4 + T cells (median, IQR) cells/μl | 170 (100–272) |
3TC Lamivudine, TDF Tenofovir, NRTIs Nucleoside reverse transcriptase inhibitor, NNRTIs Non-nucleoside reverse transcriptase inhibitor, Lpv/r Lopinavir/ritonavir